Ovarian Cancer Recurrent clinical trials

Explore recruiting ovarian cancer recurrent clinical trials.

Recruiting ovarian cancer recurrent studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ovarian Cancer Recurrent trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse 022/ENGOT ov84/GOG-3103)

Spain, Austria, Belgium, Czechia, Denmark, Finland +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination with Niraparib and ZN-c3 Monotherapy in Subjects with Platinum-resistant Ovarian Cancer.

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-ov65).

Finland, Germany, Italy, Denmark, France, Norway +4 more

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase 2 Study of Avutometinib (VS-6766, a Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 201)

Belgium, Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

MITO 31- A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The MITO 31 translational study.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084)

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Ovarian Cancer Recurrent trials by city

Ovarian Cancer Recurrent in Toronto Ovarian Cancer Recurrent in Vancouver Ovarian Cancer Recurrent in Montreal Ovarian Cancer Recurrent in Calgary Ovarian Cancer Recurrent in Edmonton Ovarian Cancer Recurrent in Ottawa Ovarian Cancer Recurrent in Winnipeg Ovarian Cancer Recurrent in Quebec City Ovarian Cancer Recurrent in Hamilton Ovarian Cancer Recurrent in Kitchener Ovarian Cancer Recurrent in London Ovarian Cancer Recurrent in Halifax Ovarian Cancer Recurrent in New York Ovarian Cancer Recurrent in Los Angeles Ovarian Cancer Recurrent in Chicago Ovarian Cancer Recurrent in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease